Eden wins the triple and bags £3m
The contracts cover a combination of development and contract manufacturing services, and demonstrate “Eden Biodesign's continued international growth,” according to the company.
Two of the contracts are with new clients, one based in Asia and the other in Continental Europe. The third contract is for a new therapeutic with an existing UK client. Eden said that all three could lead to “significant further sales.”
Dr. Crawford Brown, CEO of Eden, said: “we put our success down to our growing track record, particularly overseas.”
“We are optimistic that we will be able to make further announcements of several more significant contract wins in the next few weeks and several exciting technology collaborations and partnerships in the coming months," he added.
Eden's National Biomanufacturing Centre in Speke, Liverpool, was cleared in May 2006 by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to produce investigational medicinal products for clinical trials.
Earlier that year Eden won the contract to operate the NBC – which is owned by the Northwest Development Agency and at the heart of a £34.25m government-funded initiative to help biotechnology start-ups get their product ideas into clinical trials and also establish England's Northwest as one of the top biomanufacturing hubs in Europe.
Earlier this year the company announced plans to build another manufacturing facility at Research Triangle Park in North Carolina, US, in order to offer its services more efficiently to companies on both sides of the Atlantic.
Brown said that Eden is accelerating its development plans in North America, with additional recruitment planned to support the growing client base and expanding project portfolio.
